Literature DB >> 10073601

The intrarenal vascular lesions associated with primary antiphospholipid syndrome.

D Nochy1, E Daugas, D Droz, H Beaufils, J P Grünfeld, J C Piette, J Bariety, G Hill.   

Abstract

Even 10 yr after the identification of the antiphospholipid syndrome (APS), renal involvement in the course of APS is still relatively unrecognized, and is probably underestimated. The association of anticardiolipin antibodies and/or lupus anticoagulant with the development of a vaso-occlusive process involving numerous organs is now confirmed. In a multicenter study, 16 cases of "primary" APS (PAPS) were found and followed for 5 yr or more, all with renal biopsy. In all 16 cases of PAPS, there was a vascular nephropathy characterized by small vessel vaso-occlusive lesions associated with fibrous intimal hyperplasia of interlobular arteries (12 patients), recanalizing thrombi in arteries and arterioles (six patients), and focal cortical atrophy (10 patients). In combination, these led to progressive destruction of the kidney, accelerated by acute glomerular and arteriolar microangiopathy in five patients. Focal cortical atrophy is a distinctive lesion, present in 10 biopsies, and likely represents the histologic and functional renal analogue to the multiple cerebral infarcts detected on imaging studies. The clinical hallmark of this vascular nephropathy in PAPS is systemic hypertension, only variably associated with renal insufficiency, proteinuria, or hematuria. The ensemble of histologic renal lesions defined in this study should aid in the separation of the lesions found in cases of secondary APS, especially systemic lupus erythematosus, into those lesions related to APS and those related to the underlying disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073601     DOI: 10.1681/ASN.V103507

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  58 in total

Review 1.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

Review 2.  Histopathology of lupus nephritis.

Authors:  Konstantinos Giannakakis; Tullio Faraggiana
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

Review 3.  Difficult clinical situations in the antiphospholipid syndrome.

Authors:  Renata Ferreira Rosa; Michelle Remião Ugolini-Lopes; Audrey Krüse Zeinad-Valim; Elbio D'Amico; Danieli Andrade
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

4.  High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.

Authors:  Nicolas Pallet; Iadh Mami; Caroline Schmitt; Zoubida Karim; Arnaud François; Marion Rabant; Dominique Nochy; Laurent Gouya; Jean-Charles Deybach; Yichum Xu-Dubois; Eric Thervet; Hervé Puy; Alexandre Karras
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

Review 5.  Renal involvement in antiphospholipid syndrome.

Authors:  Francisco Vileimar Andrade de Azevedo; Diego Germano Maia; Jozelio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  Rheumatol Int       Date:  2018-05-05       Impact factor: 2.631

6.  Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.

Authors:  C Hamid; K Norgate; D P D'Cruz; M A Khamashta; M Arno; J D Pearson; G Frampton; J J Murphy
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

7.  Pauci-immune glomerulonephritis associated with primary antiphospholipid syndrome.

Authors:  Fatih Dede; Yasin Simsek; Ali Riza Odabas; Deniz Ayli; Mansur Kayatas
Journal:  Rheumatol Int       Date:  2007-09-27       Impact factor: 2.631

Review 8.  Renal manifestations of the antiphospholipid syndrome.

Authors:  David D'Cruz
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 9.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 10.  Renal involvement in primary antiphospholipid syndrome.

Authors:  Carmelita Marcantoni; Carmela Emmanuele; Francesco Scolari
Journal:  J Nephrol       Date:  2016-05-19       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.